Efavirenz + 2 NRTIs for Maintenance Therapy

Efavirenz + 2 NRTIs performed better than efavirenz + lopinavir/ritonavir as a class-sparing maintenance regimen among suppressed patients who switched from 3- or 4-drug PI- or NNRTI-based therapy.

Potent combination antiretroviral therapy reduces HIV morbidity and mortality, but the complexity and tolerability of the initial regimens can contribute to virologic failure and nonadherence. Data are limited regarding long-term outcomes with class-sparing maintenance therapy after achievement of virologic suppression on an initial induction regimen.

In this ACTG trial, 236 patients with viral loads ≤200 copies/mL after 18 or more months on an initial 3- or 4-drug PI- or NNRTI-based regimen were randomized to receive one of two simplified, class-sparing maintenance regimens: efavirenz (600 mg once daily) + 2 NRTIs, or lopinavir/ritonavir (533 mg/133 mg twice daily) + efavirenz (600 mg once daily). To be eligible for the study, patients had …

Reviewing Author

Keith Henry, MD

Efavirenz + 2 NRTIs for Maintenance Therapy

Topics

Reviewing Author